SUPN — Supernus Pharmaceuticals Inc. stock price and chart

SUPN

$41.23+3.49%

as of close, Oct 20, 2026

☾ AH $41.23 +3.49%

Supernus Pharmaceuticals Inc.Stock · HealthcareRussell 2000 · 0.08% of IWMNasdaq Composite · 0.008% of ONEQUS Stock Market · 0.004% of VTIRussell 3000 · 0.003% of IWV

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEE

20162019202120242026

20.025.030.035.040.045.050.055.005.0M10.0M$41.23

2026-10-20

Price$41.23

MA20$45.19

MA50$47.38

Vol5.1M

What would $1,000 invested in SUPN be worth today? →

SUPN returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $41.23
YTD price return: -17.04%
YTD total return: -17.04%
Next earnings: Nov 3, 2026
Market cap: 2.4B2016-12 1.3B2026-10 2.4B+91.6% over the window
Enterprise value: 2.3B
Shares outstanding: 58.1M2016-06 49.5M2026-06 58.1M+17.4% over the window
52W low: $37.54
52W high: $59.68
From 52W high: -30.91%
From 52W low: +9.83%
52W range: 17%

Volume

Rel volume: 1.46×
30D volume: 805.3K
30D $ vol: 33.7M

Fundamentals

Sales (ttm): 830.4M2016-06 178.9M2026-06 830.4M+364.3% over the window
Sales/share: $14.292016-06 $3.612026-06 $14.29+295.4% over the window
EPS (ttm): -$1.912016-06 $0.482026-06 -$1.91-498.7% over the window
FCF (ttm): 18.8M2016-06 30.8M2026-06 18.8M-38.9% over the window
FCF/share: $0.322016-06 $0.622026-06 $0.32-48.0% over the window
Book value/share: $17.742016-06 $2.232026-06 $17.74+696.8% over the window
Net margin: -13.23%2016-06 14.4%2026-06 -13.2%-191.6% over the window
ROE: -10.66%2016-06 23.4%2026-06 -10.7%-145.4% over the window
ROA: -7.69%2016-06 11.8%2026-06 -7.7%-165.1% over the window
Current ratio: 2.082016-06 1.692026-06 2.08+23.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +24.87%2025-06-30 → 2026-06-30665.1M → 830.4M (+24.9% total)+9.41%2023-06-30 → 2026-06-30634M → 830.4M (+31.0% total)+7.78%2021-06-30 → 2026-06-30571M → 830.4M (+45.4% total)+16.60%2016-06-30 → 2026-06-30178.9M → 830.4M (+364.3% total)
FCF: -89.91%2025-06-30 → 2026-06-30185.9M → 18.8M (-89.9% total)-35.82%2023-06-30 → 2026-06-3071.1M → 18.8M (-73.6% total)-30.77%2021-06-30 → 2026-06-30118.1M → 18.8M (-84.1% total)-4.81%2016-06-30 → 2026-06-3030.8M → 18.8M (-38.9% total)
Shares: +3.67%2025-06-30 → 2026-06-3056.1M → 58.1M (+3.7% total)+2.11%2023-06-30 → 2026-06-3054.6M → 58.1M (+6.5% total)+1.81%2021-06-30 → 2026-06-3053.1M → 58.1M (+9.4% total)+1.62%2016-06-30 → 2026-06-3049.5M → 58.1M (+17.4% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +20.46%2025-06-30 → 2026-06-30$11.86 → $14.29 (+20.4% total)+7.15%2023-06-30 → 2026-06-30$11.61 → $14.29 (+23.0% total)+5.87%2021-06-30 → 2026-06-30$10.74 → $14.29 (+33.0% total)+14.74%2016-06-30 → 2026-06-30$3.61 → $14.29 (+295.4% total)
FCF/share: -90.26%2025-06-30 → 2026-06-30$3.31 → $0.32 (-90.2% total)-37.15%2023-06-30 → 2026-06-30$1.30 → $0.32 (-75.2% total)-32.00%2021-06-30 → 2026-06-30$2.22 → $0.32 (-85.5% total)-6.33%2016-06-30 → 2026-06-30$0.62 → $0.32 (-48.0% total)
Book value/share: -6.50%2025-06-30 → 2026-06-30$18.97 → $17.74 (-6.5% total)+1.73%2023-06-30 → 2026-06-30$16.85 → $17.74 (+5.3% total)+3.72%2021-06-30 → 2026-06-30$14.78 → $17.74 (+20.0% total)+23.07%2016-06-30 → 2026-06-30$2.23 → $17.74 (+696.8% total)
Price: -20.09%2025-10-20 → 2026-10-20$51.59 → $41.23 (-20.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.25%2023-10-20 → 2026-10-20$24.31 → $41.23 (+69.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+6.64%2021-10-20 → 2026-10-20$29.90 → $41.23 (+37.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+7.13%2016-10-19 → 2026-10-20$20.71 → $41.23 (+99.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -20.09%2025-10-20 → 2026-10-20$51.59 → $41.23 (-20.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.25%2023-10-20 → 2026-10-20$24.31 → $41.23 (+69.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+6.64%2021-10-20 → 2026-10-20$29.90 → $41.23 (+37.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+7.13%2016-10-19 → 2026-10-20$20.71 → $41.23 (+99.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -21.5×2016-12 14.932026-10 -21.81-246.0% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 41.6×2016-12 27.312026-10 -18.37-167.3% over the window
Fwd P/E: 9.0×
P/S (ttm)Market cap ÷ TTM revenue.: 2.9×2016-12 6.372026-10 2.89-54.7% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.3×2016-12 7.212026-10 2.32-67.8% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 127.6×2016-12 20.982026-10 127.57+508.2% over the window
EV/EBITDA (fy): 77.1×
EV/Sales (ttm): 2.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.78%2016-09 4.8%2026-06 0.7%-85.4% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 58.1M ÷ 56.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -3.67%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-3.67%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.8B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -3.67%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-50.1M) ÷ today's market cap ($2.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -2.09%2016-09 -0.2%2026-06 -1.9%+1027.8% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-50.1M + TTM dividends $0) ÷ today's market cap ($2.4B). Same caveat as the cash buyback yield.: -2.09%2016-09 -0.2%2026-06 -1.9%+1027.8% over the window

Vs own 10Y history

P/E: 88th
P/OI: 85th
P/S: 38th
P/B: 56th
P/FCF: 97th

Bar = where today’s multiple sits in SUPN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+3.49%

-1.86%

-1.83%

-13.05%

YTD

-17.04%

-20.08%

+37.89%

Financial statements

Open full SUPN financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

SUPN — Supernus Pharmaceuticals Inc. price, chart and key statistics